Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

12. Dezember 2011 08:00 ET | Quelle: Mateon Therapeutics

OXiGENE and Azanta A/S Establish Partnership to Provide ZYBRESTAT(TM) for ATC in Europe on Named Patient, Compassionate Use Basis

SOUTH SAN FRANCISCO, Calif., and HELLERUP, Denmark, Dec. 12, 2011 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat...
07. Dezember 2011 08:00 ET | Quelle: Mateon Therapeutics

OXiGENE Presents Data From FAVOR Study of ZYBRESTAT in PCV

SOUTH SAN FRANCISCO, Calif., Dec. 7, 2011 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases,...
28. November 2011 08:30 ET | Quelle: Mateon Therapeutics

OXiGENE Announces Purchase Agreement for Up to $20 Million With Lincoln Park Capital

SOUTH SAN FRANCISCO, Calif., Nov. 28, 2011 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases,...
09. November 2011 16:00 ET | Quelle: Mateon Therapeutics

OXiGENE Reports Third Quarter 2011 Financial Results

SOUTH SAN FRANCISCO, Calif., Nov. 9, 2011 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases,...
03. November 2011 16:30 ET | Quelle: Mateon Therapeutics

OXiGENE Reports Final Data From Phase 2 FALCON Study of ZYBRESTAT in Non-Small Cell Lung Cancer

SOUTH SAN FRANCISCO, Calif., Nov. 3, 2011 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases,...
02. November 2011 07:00 ET | Quelle: Mateon Therapeutics

OXiGENE Announces Third Quarter 2011 Earnings Conference Call and Webcast

SOUTH SAN FRANCISCO, Calif., Nov. 2, 2011 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases,...
14. September 2011 13:15 ET | Quelle: Mateon Therapeutics

OXiGENE Presents Data Confirming Survival Benefit of ZYBRESTAT in Patients With Anaplastic Thyroid Cancer

SOUTH SAN FRANCISCO, Calif., Sept. 14, 2011 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases,...
09. September 2011 16:00 ET | Quelle: Mateon Therapeutics

OXiGENE Announces Changes to Board of Directors

SOUTH SAN FRANCISCO, Calif., Sept. 9, 2011 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases,...
07. September 2011 16:30 ET | Quelle: Mateon Therapeutics

OXiGENE to Present Additional ZYBRESTAT(TM) Survival Data at European Thyroid Association Annual Meeting

SOUTH SAN FRANCISCO, Calif., Sept. 7, 2011 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases,...
01. September 2011 08:00 ET | Quelle: Mateon Therapeutics

OXiGENE Announces Restructuring to Focus Resources on Promising Earlier Stage Clinical Programs

SOUTH SAN FRANCISCO, Calif., Sept. 1, 2011 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases,...

Vorherige Seite